Draft:David M. Goldenberg

David M. Goldenberg (born August 02, 1938) is an American novelist, retired physician-scientist, retired biotechnology executive, and philanthropist. He is the founder of several healthcare-related organizations, including Immunomedics, IBC Pharmaceuticals, The Center for Molecular Medicine and Immunology, The Garden State Cancer Center, and the Ephraim McDowell Community Cancer Network. In addition, Goldenberg is the author of The Scenturion Spy novel series, which includes his olfaction and cancer research.

Early life and education

Born and raised in Brooklyn, New York [4], Goldenberg left Stuyvesant High School in the 10th grade (1954), and then went to Shimer College, Illinois, on a Ford Foundation Early Entrance Scholarship. Following Shimer College, Goldenberg attended the University of Chicago and received an SB in 1958. Later, he moved to West Germany and acquired an ScD from the University of Erlangen Nuremberg Faculty of Natural Sciences in 1965 and an MD from Heidelberg University Faculty of Medicine in the following year. He then completed his postgraduate training at the University Hospital of Erlangen in 1967.[4] His ScD dissertation was titled Thresholds of Odor Mixtures in Men, and his MD dissertation was titled The Use of Several New Human Tumor Systems in Experimental Cancer Research. Both were published in peer-reviewed journals.

Career

Academic, researcher, and philanthropist

After graduating from the University of Chicago in 1958, Goldenberg joined the Sloan-Kettering Institute as a research assistant for a year. In 1960, he was a guest researcher at the Institute for Experimental Cancer Research at Heidelberg University, where he also matriculated in the Faculty of Medicine. He continued medical studies at the University of Erlangen-Nuremberg, while also matriculating for a doctorate in natural sciences. Between 1964 and 1967, he was a research associate and founder of the cancer research laboratory at the University Medical Clinic in Erlangen, and then became the head of the Department of Clinical and Experimental Oncology at the University Surgical Clinic until the end of 1968, when Goldenberg returned to the United States to join the University of Pittsburgh School of Medicine as associate research professor of pathology.

From 1970 to 1972, he served as an associate professor of pathology, and then also the head of the Medical Genetics Unit at Temple University Health Sciences in Philadelphia. After Temple University, Goldenberg became an associate professor of pathology at the University of Kentucky Medical Center, promoted to professor in 1973. In Kentucky, he also directed the clinical cytogenetics laboratory and formed the Division of Experimental Pathology, which collaborated with the Graduate School in Biology. Goldenberg also founded the University of Kentucky’s cancer center, The Ephraim McDowell Community Cancer Network, which received support from the National Cancer Institute and the NIH, and the McDowell Cancer Research Foundation. He also served as a secretary-treasurer of the Kentucky Cancer Commission, which he helped establish through an Act of the Kentucky General Assembly.

Following Kentucky, Goldenberg moved to New Jersey in 1983, becoming an adjunct professor of medicine and surgery (1983-93) at the New Jersey Medical School in Newark, while founding The Center for Molecular Medicine and Immunology (CMMI), and then The Garden State Cancer Center, where he served as the president. Between 1993 and 1995, he taught graduate students at New York Medical College as an adjunct professor of microbiology and immunology.

Businessman

Goldenberg served as one of the founding trustees of the Association of Community Cancer Centers (1977-79). He was on the board of directors for the Commission on Radioisotopes and Radiopharmaceuticals (CORAR) from 1995 to 2000. Goldenberg has been a trustee of The Center for Molecular Medicine Foundation, The Garden State Cancer Center Foundation, the Escalon Foundation, and the Goldenberg Family Foundation.

Goldenberg founded Immunomedics, a publicly-traded biotechnology company[3], in 1982 and its subsidiary IBC Pharmaceuticals in 2000. He served as the chairman of both companies until late 2017, when the companies were acquired by Hedge Funds.  In 2021, Gilead Sciences purchased the companies.

Immunomedics commercialized two antibody-based diagnostic imaging agents (CEA-Scan and LeukoScan), and an antibody-drug conjugate, Trodelvy, for treating several solid cancer types, and also invented other radio- and drug-immunoconjugates for cancer therapy.

Novelist and editor

In 2022, Goldenberg published The Scenturion Spy, Book One: Becoming a Spy, and then its sequel, The Scenturion Spy, Book Two: Settling in Moscow, in the following year. Both of his novels involve spying for the CIA in Moscow to learn of their olfactory bioweapons research, using the cover of studying olfactory drugs as a potential neurological disease therapy, while the protagonist also continued his cancer research at a New York medical school.

Since 1995, Goldenberg has served on the editorial boards of over 25 medical and scientific journals, including Oncology Reports, The International Journal of Biological Markers, Tumor Biology, Journal of Nuclear Medicine, Journal of Cancer Research and Clinical Oncology, Diagnostic Oncology, and Cancer. He edited 13 supplements to Cancer Research, Clinical Cancer Research, and Cancer on cancer imaging and therapy with radiolabeled antibodies.

Personal life

Goldenberg married Hildegard Gruenbaum in 1961 and divorced in 1996. He then married Cynthia Sullivan in 1997. Goldenberg had 6 children from his first marriage and 12 grandchildren. Through his second marriage, he has 2 step-children and 4 step-grandchildren.

Awards, honors, and fellowships

• New Jersey American Cancer Society Honoree, May 5, 2018.
• 37th Thomas Alva Edison Patent Award – co-recipient – in Biotechnology, from the Research & Development Council of New Jersey, for US Patent 9,1315,567, “T-cell redirecting bispecific antibodies for treatment of disease,” 2016.
• 35th Thomas Alva Edison Patent Award – co-recipient – in Biotechnology, from the Research & Development Council of New Jersey, for US Patent 7,999,083, “Immunoconjugates with an intracellularly-cleavable linkage,” 2014.
• 33rd Thomas Alva Edison Patent Award – co-recipient – in Biotechnology, from the Research & Development Council of New Jersey, for US Patent 7,521,056, “Stably Tethered Structures of Defined Compositions with Multiple Functions of Binding Sites,” 2012.
• 32nd Thomas Alva Edison Patent Award - co-recipient -in Medical Imaging, from the Research & Development Council of New Jersey, for US Patent 7,597,876, “Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules,” 2011
• Innovative Hero – Individual finalist, NJBIZ Healthcare Heroes Awards Program, 2009
• Inventor of the Year, New Jersey Inventors Hall of Fame, Research and Development Council of NJ, 2005
• Paul C. Aebersold Award for Outstanding Achievements in Basic Science Applied to Nuclear Medicine, Society of Nuclear Medicine, 2005
• CLAS’ Distinguished Scientist Award, Clinical Ligand Assay Society, 2004
• Garden State Cancer Center Special Scientific Achievement Award, 2003
• Elis Bervin Lecture and Medal, Swedish Oncology Society, 2002
• Ted Bloch Memorial Lecture, Southwestern Chapter, Society of Nuclear Medicine, 1999
• Sarabhai Memorial Oration, 26th Annual Indian Society of Nuclear Medicine Meeting, Cuttack, India, 1994
• Abbott Award - co-recipient - International Society for Oncodevelopmental Biology and Medicine, 1994
• The Ninth Otto Herz Memorial Lecture in Cancer Res., Tel Aviv University, 1991
• 3M Mayneord Memorial Award and Lecture, British Institute of Radiology, 1991
• Outstanding Investigator Award Grant, National Cancer Institute, 1985 and 1992
• American Cancer Society, Essex County, Award for Research, 1988
• New Jersey Senate Resolution, Award for Excellence in Cancer Research 1986
• New Jersey Pride Award in Science and Technology, NJ Monthly, 1986
• New Jersey Assembly Resolution, Award for Excellence in Cancer Research, 1985
• Honorary Member, Argentine Cancer Association, 1981
• Silver Medallion and Certificate from German Fund for Cancer Research, Bonn 1979
• University of Kentucky Research Foundation Award, 1978
• Fellow, German Research Society at University of Erlangen-Nuremberg, 1966-67
• Bavarian State Scholarship for Foreign Students, 1964
• Tuition Aid, University of Erlangen-Nuremberg, 1963-64
• U.S.P.H.S. Predoctoral Summer Fellowship (at Columbia Univ., NY), Summer 1963
• Ford Foundation Early Entrance Scholarship, 1954-56
• Manufacturers Trust Company Essay Award, 1953

Selected patents

• Method of Producing Carcinoembryonic Antigens. United States Patent US 3,865,689. February 11, 1975.
• Tumor Localization and Therapy with Labeled Antibody Fragments Specific to Tumor-Associated Markers. United States Patent US 4,331,647. May 25, 1982.
• Tumor Localization and Therapy with Labeled Anti-CEA Antibody. United States Patent US 4,348,376. September 7, 1982.
• Tumor Localization and Therapy with Labeled Antibodies Specific to Intracellular Tumor-Associated Markers. United States Patent US 4,361,544. November 30, 1982.
• Tumor Localization and Therapy with Labeled Antibodies to Cell Surface Antigens (tumor imaging, therapy). United States Patent US 4,444,744. April 24, 1984.
• Tumor Localization and Therapy with Labeled Antibodies Specific to Intracellular Tumor-Associated Markers. United States Patent US 4,460,559. July 17, 1984.
• Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules. United States Patent 9,115,172. August 25, 2015.
• Class I Anti-CEA Antibodies and Uses Thereof. United States Patent 9,139,657. September 22, 2015.
• Humanized Anti-CD22 Antibody. United States Patent 9,139,649. September 22, 2015.
• Immunoconjugates with an Intracellularly-Cleavable Linkage. United States Patent 9,138,485. September 22, 2015.
• Immunoconjugates with an Intracellularly-Cleavable Linkage. United States Patent 9,198,978. December 01, 2015.

Selected research articles

• Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. DM Goldenberg, F DeLand, E Kim, S Bennett, FJ Primus, JR van Nagell Jr, New England Journal of Medicine 298 (25), 1384-1388, 1978
• Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. A Bardia, IA Mayer, LT Vahdat, SM Tolaney, SJ Isakoff, JR Diamond, New England Journal of Medicine 380 (8), 741-751, 2019
• Targeted therapy of cancer with radiolabeled antibodies.,DM Goldenberg, Journal of Nuclear Medicine 43 (5), 693-713, 2002
• Sacituzumab govitecan in metastatic triple-negative breast cancer., A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, New England Journal of Medicine 384 (16), 1529-1541, 2021
• A novel method of 18F radiolabeling for PET. WJ McBride, RM Sharkey, H Karacay, CA D'Souza, EA Rossi, Journal of Nuclear Medicine 50 (6), 991-998, 2009
• Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen., DM Goldenberg, EE Kim, FH DeLand, S Bennett, FJ Primus, Cancer Research 40 (8_Part_2), 2984-2992, 1980
• Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy., DM Goldenberg, RM Sharkey, G Paganelli, J Barbet, JF Chatal, Journal of Clinical Oncology 24 (5), 816, 2006
• Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. , TM Behr, DM Goldenberg, W Becker, European Journal of Nuclear Medicine 25, 201-212, 1998
• Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. ,RM Sharkey, DM Goldenberg, CA: A Cancer Journal for Clinicians 56 (4), 226-243, 2006
• Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G., DM Goldenberg, DF Preston, FJ Primus, HJ Hansen , Cancer Research 34 (1), 1-9, 1974
• On some vegetative reactions following olfactory stimulation in humans. W Neuhaus, DM Goldenberg Experientia 22(3):174-6, 1966.
• On the progression of malignancy: a hypothesis.  DM Goldenberg, Klinische Wochenschrift 46(16):898-9, 1968.
• In vivo hybridisation of human tumour and normal hamster cells., DM Goldenberg, RA Pavia RA, MC Tsao , Nature 250(5468):649-51, 1974.
• Malignant potential of murine stromal cells after transplantation of human tumors into nude mice., DM Goldenberg, RA Pavia , Science 212(4490):65-7, 1981.
• In vivo horizontal oncogenesis by a human tumor in nude mice. , DM Goldenberg, RA Pavia ,Proceedings of the National Academy of Sciences USA 79(7):2389-92, 1982.
• Clinical radioimmunodetection of cancer with radioactive antibodies to human chorionic gonadotropin.  , DM Goldenberg, EE Kim, FH DeLand, JR van Nagell Jr, N. Javadpour , Science 208(4449):1284-6, 1980.
• Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. DM Goldenberg, SA Gaffar, SJ Bennett, JL Beach , Cancer Research 41(11 Pt 1):4354-60, 1981.
• Radioimmunodetection of prostatic cancer.  In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. DM Goldenberg, FH DeLand, SJ Bennett, FJ Primus, MO Nelson, RC Flanigan, JW McRoberts, AW Bruce, DE Mahan, Journal of the American Medical Association 250(5):630-5, 1983.
• Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. DM Goldenberg, EE Kim, SJ Bennett, MO Nelson, FH Deland, Gastroenterology 84(3):524-32, 1983.
• Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system. DM Goldenberg, RM Sharkey, FJ Primus, E Mizusawa, MF Hawthorne Proceedings of the National Academy of Sciences USA 81(2):560-3, 1984.
• Imaging of primary and metastatic liver cancer with 131I monoclonal and polyclonal antibodies against alphafetoprotein. DM Goldenberg, H Goldenberg, E Higginbotham-Ford, D Shochat, E Ruoslahti , Journal of Clinical Oncology 5(11):1827-35, 1987.